Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Tesofensine 500mcg research peptide vial

Click to enlarge

Tesofensine 500mcg x 100ct

Name: Tesofensine 500mcg x 100ct
SKU: TESO500MCG
Availability: InStock

$200.00

≥99% purity · HPLC verified · MS confirmed How we test →

Products will arrive in a lyophilized (powder) form for maximum stability

Tesofensine (NS2330) is a triple monoamine reuptake inhibitor of serotonin, norepinephrine, and dopamine, originally developed by NeuroSearch for neurodegenerative disease and later repositioned for obesity research. Phase II trials reported weight reductions roughly double those of earlier approved agents, with later-stage trials following. It remains an investigational compound, not approved for any use; supplied in a 500mcg, 100-count format, for research use only.

Add to compare

Add to wishlist

Add to compare

Add to wishlist

Free shipping on orders of $200+

COMPOUND NAME

Tesofensine

SYNONYMS

NS-2330, 3-[bis(benzyl)methylamino]-2-(ethoxymethyl)-1-(3,4-dichlorophenyl)-tropane

CAS NUMBER

195875-84-4

MOLECULAR FORMULA

C₁₇H₂₃Cl₂NO

MOLECULAR WEIGHT

~328.3 g/mol

STRUCTURE

Synthetic triple monoamine reuptake inhibitor

PEPTIDE SEQUENCE

N/A; Not a peptide

CHEMICAL STRUCTURE

Tesofensine compound molecular structure

Molecular Formula: C₁₇H₂₃Cl₂NO

Source: PubChem

Tesofensine acts by competitively inhibiting the reuptake of dopamine, norepinephrine, and serotonin in the central nervous system. By blocking their respective transporters, tesofensine prolongs monoamine signaling in key brain regions involved in appetite and energy homeostasis, including the lateral hypothalamus. This results in suppressed food intake, increased satiety, and enhanced energy metabolism. Tesofensine’s unique triple reuptake inhibition differentiates it mechanistically from other anti-obesity agents targeting only one or two neurotransmitter systems^1-4.

Tesofensine exhibits potent appetite suppressant and weight-reducing effects in animal models and clinical studies. In rodents and humans, tesofensine significantly decreases caloric intake, promotes loss of body fat (especially visceral fat), and improves metabolic profiles (reducing cholesterol, triglycerides, and insulin). It has shown greater efficacy for weight loss than sibutramine and rimonabant in preclinical head-to-head studies. Tesofensine also modulates hypothalamic neuronal activity, specifically silencing GABAergic neurons that stimulate feeding, and augments fat oxidation and night-time energy expenditure. At clinically relevant doses, tesofensine generally produces mild adverse events; however, higher doses can impact heart rate and blood pressure^1-4.

Store at 2–8°C, protected from light and humidity.

Anti-obesity agents, Appetite suppressants, Monoamine reuptake inhibitors, Experimental CNS agents

Tesofensine is not approved for human use outside of a research setting. There are ongoing investigations into its synergistic effects with serotonergic agents to prolong weight loss and potentially prevent weight regain. It has a lower observed potential for abuse compared to classic stimulants and does not typically induce motor stereotypy at therapeutic doses

Property

Description

CAS Number

195875-84-4

Molecular Formula

C17H23Cl2NO

Molecular Weight (MW)

~328.3 g/mol

Mechanism of Action

Triple reuptake inhibitor of DA, NE, 5-HT; central appetite suppression and metabolic modulation

Biological Activity

Appetite suppression, weight loss, fat oxidation, metabolic improvements

Supplied Form

Lyophilized powder or solution (research grade)

Purity

≥99% (HPLC)

Storage

2–8°C, dry, protected from light

Drug Categories

Anti-obesity agent, appetite suppressant, reuptake inhibitor

Additional Notes

Not for human or veterinary use; low abuse potential at therapeutic doses

For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.

Tesofensine is a novel, small-molecule, synthetic derivative belonging to the phenyltropane class, designed as a potent triple reuptake inhibitor of dopamine, norepinephrine, and serotonin^1,2. Developed originally for neurodegenerative diseases and later repurposed for obesity, tesofensine demonstrated superior efficacy in reducing body weight and adiposity compared to other anti-obesity drugs in both animal models and clinical studies. Its primary action is central. It acts synergistically and enhances monoaminergic signaling at multiple brain sites involved in appetite and energy regulation, with notable efficacy in suppressing caloric intake and sustaining weight loss². Additionally, it modulates metabolic markers such as cholesterol, triglycerides, and plasma insulin, and has been associated with improvements in quality-of-life parameters during clinical trials^1-4. An important aspect of tesofensine’s pharmacology is its low potential for abuse relative to classical stimulants, likely due to its differentiated neurochemical impact and lack of pronounced behavioral stereotypy at therapeutic doses. Its safety profile is favorable at moderate doses, with most adverse effects being mild or transient, such as dry mouth, insomnia, and mild increases in heart rate^3,4.

Significantly greater weight loss in obese versus lean animals; superior to sibutramine/rimonabant in animal models^1,3.

Silences lateral hypothalamic GABAergic neurons-blunting feeding drive and enhancing anorexigenic effect³.

Does not alter taste or palatability of sweet foods, ruling out aversive mechanisms for appetite suppression³.

Synergistic with serotonin agents such as 5-HTP to prolong and sustain weight loss, potentially delaying rebound weight gain³.

Inhibits central reuptake of dopamine, increasing extracellular DA in reward and feeding circuits (notably nucleus accumbens and hypothalamus)³.
Prolonged DA signaling reduces the hedonic drive for food, decreases food reward, and helps modulate motivational aspects of feeding^1,2.
Unlike typical stimulants, DA transporter occupancy by tesofensine does not trigger significant behavioral stereotypy at therapeutic doses^1-3.

Blocks norepinephrine reuptake, increasing synaptic NE especially in the hypothalamus and limbic regions¹.
Enhanced NE signaling increases energy expenditure (thermogenesis), heightens satiety, and further suppresses appetite².
Inhibition of NE reuptake is key to the compound’s effect in reducing food intake and boosting metabolic rate^1,2.

Blocks serotonin reuptake, raising 5-HT levels, particularly within appetite and satiety centers of the brain (hypothalamus)³.
Elevated 5-HT signals promote satiety, suppress hunger, and, via downstream signaling, reduce caloric intake³.
Synergizes with other serotonergic agents (like 5-HTP) to prolong weight loss and decrease risk of rebound³.

Inhibits activity of LH GABAergic neurons that normally stimulate feeding behavior³.
Experimental silencing of these neurons potentiates tesofensine’s anorexigenic effect, highlighting a direct action at neural circuits controlling energy balance³.

Route of Administration

Oral

Dosing Frequency

Once daily

Half-Life

284 hours

Route of Administration: Oral (clinical), subcutaneous (preclinical/animal studies)
Dosing Frequency: Once daily
Half-Life: Long (t½ up to ~284 hours in humans)

Supplied as a lyophilized powder or aqueous solution.
Store at 4°C in a dry, light-protected environment.

Trial ID

Title

Phase

Study Type

Sponsor

NCT00481104

Evaluation of Long-Term Safety of Tesofensine in Patients With Obesity

Interventional

NeuroSearch A/S

NCT00428415

Effect of Tesofensine on Energy Balance in Humans.

1/2

Interventional

NeuroSearch A/S

NCT02737891

Safety and Efficacy Study of Tesofensine/?Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Interventional

Saniona

NCT03149445

Co-administration of Tesofensine/?Metoprolol in Subjects With Prader-Willi Syndrome (PWS) (2016-003694-18)

Interventional

Saniona

Bello, N.T. & Zahner, M.R. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Expert Opin. Investig. Drugs 18, 1717–1726 (2009).

Appel, L., Bergström, M., Buus Lassen, J. & Långström, B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET. Eur. Neuropsychopharmacol. 24, 251–261 (2014).

Rascol, O. et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch. Neurol. 65, 577–583 (2008).

Perez, C.I. et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS ONE 19, e0300544 (2024).

This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →